Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs NTCD M3 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Sponsors Shire
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2013 Results published in the Media Release.
- 22 Apr 2013 Results were reported in a ViroPharma media release.